A Clinical Study of JMT101 in Combination With Osimertinib Versus Osimertinib Alone as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Sensitive Mutations

PHASE3RecruitingINTERVENTIONAL

Enrollment

516

Participants

Timeline

Start Date

October 23, 2024

Primary Completion Date

September 30, 2026

Study Completion Date

May 30, 2029

Conditions

Locally Advanced or Metastatic Non-squamous NSCLCHarboring EGFR Sensitive Mutations NSCLCPreviously Untreated Systematically NSCLC

Interventions

DRUG

JMT101

JMT101 is a recombinant humanized anti-EGFR monoclonal antibody.

DRUG

Osimertinib

EGFR TKI

Trial Locations (1)

RECRUITING

Sun Yat sen University Cancer Prevention and Treatment Center, Guangzhou

All Listed Sponsors

lead

Shanghai JMT-Bio Inc.

INDUSTRY